Cargando…
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156211/ https://www.ncbi.nlm.nih.gov/pubmed/32205092 http://dx.doi.org/10.1016/j.jmii.2020.03.005 |